Wisp Expands into Women-Centric Longevity Care with New Healthy…

Event summary

Wisp launched a new Longevity and Healthy Aging vertical on March 10, 2026, offering five science-backed treatments including glutathione, NAD+, and low-dose naltrexone.
The move follows a survey of nearly 2,000 women revealing a significant longevity gap, with 75% prioritizing long-term health but only 11% feeling current telehealth tools provide control.
Wisp is positioning itself as a lifelong partner for women's health, moving beyond reproductive health into preventative wellness and peptides.
The company plans to expand offerings to include mitochondrial support, cognitive health pathways, menopause-adjacent longevity care, and preventive diagnostics.

The big picture

Wisp's expansion into longevity care addresses a critical gap in the market, where women's specific needs have been overlooked amid broader biohacking trends. With 1.8 million patients nationwide and majority ownership by WELL Health Technologies Corp., Wisp is well-positioned to capitalize on the growing demand for preventative, women-centric healthcare solutions. The move reflects a strategic shift towards comprehensive healthspan management, moving beyond traditional reproductive health.

What we're watching

Market Differentiation: Whether Wisp can sustain its lead in women-centric longevity care as competitors enter the space.
Regulatory Scrutiny: The pace at which regulatory bodies review and approve new longevity treatments for women.
Patient Adoption: How quickly women adopt these new longevity services given the current fragmentation in the telehealth market.

Our editorial coverage: